Michela Guglieri - Concepedia

Author

Michela Guglieri

Also Known As

Anne-Katrin Guettsches, Christine Wondrusch Haschke, Guglieri, M, J Bibbiani, Katherine Bushby, M Guglieri, M. Guglieri, Michela Guglieri, Mickael Guglieri, Sarah Gregson

278

Publications

9.4K

Citations

H-Index

121

Concepts

All Affiliations

Newcastle University University College London Great Ormond Street Hospital Newcastle upon Tyne Hospitals NHS Foundation Trust Institut de Myologie

About

Michela Guglieri is an author at Newcastle University specializing in medicine, health sciences, and clinical trials.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	23	28	3.4K
2	Health Sciences	9	9	482
3	Public Health	6	7	368
4	Engineering	4	4	426
5	Business	1	1	18

Michela Guglieri

Publications

Citations

H-Index

Page 1

	Year	Citations
Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study Sebahattin Çirak, Virginia Arechavala‐Gomeza, Michela Guglieri, The Lancet Exon SkippingUrologyDuchenne Muscular DystrophyPhase 2Medicine	2011	852
Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study Maria Kinali, Virginia Arechavala‐Gomeza, Lucy Feng, The Lancet Neurology	2009	635
Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Craig M. McDonald, Craig Campbell, Ricardo Erazo Torricelli, The Lancet Rare DiseasesUrologyClinical TrialsDegenerative DiseaseRehabilitation	2017	446
Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy Diane E. Frank, Frederick J. Schnell, Cody Akana, Neurology	2020	310
Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study Thomas Voit, Haluk Topaloğlu, Volker Straub, The Lancet Neurology Placebo-controlled Phase 2MedicineDuchenne Muscular DystrophyClinical TrialsPharmacotherapy	2014	293
Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy Valeria Ricotti, Deborah Ridout, E. Scott, Journal of Neurology Neurosurgery & Psychiatry	2012	255
Autologous Transplantation of Muscle-Derived CD133+ Stem Cells in Duchenne Muscle Patients Yvan Torrente, M. Belicchi, Chiara Marchesi, Cell Transplantation Cell TherapyMuscle FunctionEngineeringImmunologyTissue Transplantation	2007	229
Clinical, molecular, and protein correlations in a large sample of genetically diagnosed Italian limb girdle muscular dystrophy patients Michela Guglieri, Francesca Magri, Maria Grazia D’Angelo, Human Mutation GeneticsGenetic EpidemiologyPathologyProtein CorrelationsDisease Gene Identification	2007	208
The burden of Duchenne muscular dystrophy Erik Landfeldt, Peter Lindgren, Christopher F. Bell, Neurology	2014	206
Recessive mutations in RYR1 are a common cause of congenital fiber type disproportion Nigel F. Clarke, Leigh B. Waddell, Sandra T. Cooper, Human Mutation Developmental AnomalyType 1Mendelian DisorderOphthalmologyGenetic Disorder	2010	172

Page 1